AR084019A1 - DERIVADOS DE BENZAMIDA COMO BLOQUEADORES DE IKACh - Google Patents

DERIVADOS DE BENZAMIDA COMO BLOQUEADORES DE IKACh

Info

Publication number
AR084019A1
AR084019A1 ARP110104423A ARP110104423A AR084019A1 AR 084019 A1 AR084019 A1 AR 084019A1 AR P110104423 A ARP110104423 A AR P110104423A AR P110104423 A ARP110104423 A AR P110104423A AR 084019 A1 AR084019 A1 AR 084019A1
Authority
AR
Argentina
Prior art keywords
alkyl
nitrile
substituents
cycloalkyl
independently selected
Prior art date
Application number
ARP110104423A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR084019A1 publication Critical patent/AR084019A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)

Abstract

Los compuestos de acuerdo con la fórmula (1) son farmacológicamente efectivos como inhibidores del canal de potasio, en particular inhibidores de la corriente del canal de potasio rectificador de entrada operada por acetilcolina (es decir bloqueadores de IKACh) y se cree que son útiles en el tratamiento de arritmias cardíacas, en particular taquiarritmias supraventriculares, tales como fibrilación auricular y palpitación auricular.Reivindicación 1: Un compuesto que tiene la estructura de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde cada R5 opcional se selecciona independientemente de fluoro, nitrilo, hidroxi, oxo, alquilo C1-5, cicloalquilo C3-5, alcoxi C1-5 o alcoxialquilo C1-5, en donde cualquier grupo alquilo, cicloalquilo o alcoxi está sustituido por 0, 1 ó 2 sustituyentes que se seleccionan independientemente de fluoro, nitrilo o hidroxi; R1 se selecciona de alquilo C1-6, cicloalquilo C3-6 o alcoxialquilo C1-6, en donde cualquier grupo alquilo, cicloalquilo o alcoxi está sustituido por 0, 1 ó 2 sustituyentes que se seleccionan independientemente de fluoro o nitrilo; R2 se selecciona de hidrógeno o alquilo C1-3; R3 se selecciona de alquilo C1-6, cicloalquilo C3-6 o alcoxialquilo C1-6, en donde cualquier grupo alquilo o cicloalquilo en estos sustituyentes está sustituido por 0, 1 ó 2 sustituyentes que se seleccionan independientemente de fluoro, nitrilo o hidroxi; cada R4 opcional se selecciona independientemente de halo, nitrilo, hidroxi, alquilo C1-3, alcoxi C1-3, alcoxialquilo C1-3 o alquil C1-3sulfuro, en donde cualquier grupo alquilo o alcoxi en estos sustituyentes está sustituido por 0, 1, 2 ó 3 sustituyentes que se seleccionan independientemente de halo, nitrilo o hidroxi; m se selecciona de 1, 2 ó 3; n se selecciona de 1 ó 2; x se selecciona de 0, 1, 2 ó 3; e y se selecciona de 0, 1, 2 ó 3.
ARP110104423A 2010-11-30 2011-11-29 DERIVADOS DE BENZAMIDA COMO BLOQUEADORES DE IKACh AR084019A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41799610P 2010-11-30 2010-11-30

Publications (1)

Publication Number Publication Date
AR084019A1 true AR084019A1 (es) 2013-04-17

Family

ID=46162787

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104423A AR084019A1 (es) 2010-11-30 2011-11-29 DERIVADOS DE BENZAMIDA COMO BLOQUEADORES DE IKACh

Country Status (5)

Country Link
US (2) US8361998B2 (es)
AR (1) AR084019A1 (es)
TW (1) TW201249795A (es)
UY (1) UY33755A (es)
WO (1) WO2012074469A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO3175985T3 (es) 2011-07-01 2018-04-28
WO2014134419A1 (en) 2013-03-01 2014-09-04 Gilead Sciences, Inc. Use of ikach blockers for the treatment of cardiac diseases
CN103664727A (zh) * 2013-12-19 2014-03-26 无锡万全医药技术有限公司 一种一锅法制备1-[(3s)-3-羟基吡咯烷-1-基]-(2s)-2-甲氨基-2-苯基乙烷的工艺
WO2016090009A1 (en) * 2014-12-02 2016-06-09 Tufts Medical Center, Inc. Atrial specific antiarrhythmics for use in treating or preventing atrial fibrillation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7700M (es) * 1968-07-17 1970-02-23
FR2326179A1 (fr) * 1975-09-30 1977-04-29 Cerm Cent Europ Rech Mauvernay Nouveaux ethers de propanolamines utilisables dans le traitement des maladies cardiovasculaires
GB8618188D0 (en) 1986-07-25 1986-09-03 Ici Plc Diamine compounds
US7435824B2 (en) 2002-04-19 2008-10-14 Bristol-Myers Squibb Company Prodrugs of potassium channel inhibitors
JPWO2004011430A1 (ja) 2002-07-25 2005-11-24 アステラス製薬株式会社 ナトリウムチャネル阻害剤
DE102004061017A1 (de) 2004-12-18 2006-06-22 Sanofi-Aventis Deutschland Gmbh Piperidinsulfonylharnstoffe und -thioharnstoffe, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
TW201249795A (en) 2012-12-16
WO2012074469A1 (en) 2012-06-07
US8361998B2 (en) 2013-01-29
US20120142659A1 (en) 2012-06-07
UY33755A (es) 2012-06-29
US20130143858A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
PH12014502697B1 (en) New diazaspirocycloalkane and azaspirocycloalkane
CR20110013A (es) Derivados de Heteroarilo como Inhibidores de DGAT1
AR088352A1 (es) Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
AR094918A1 (es) Compuestos de tetrahidropirrolotiazina como inhibidores de bace
PE20160200A1 (es) Inhibidores de bromodominios
NI201400043A (es) 4 - fenil - piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
EA201390877A1 (ru) Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
ES2531056T3 (es) Espirociclos como inhibidores de 11-beta hidroxilesteroide deshidrogenasa tipo 1
CO2019003482A2 (es) Compuestos derivados de ciclobutano o azetidina 1,3 disustituidos como inhibidores de la prostaglandina d sintasa hematopoyética
IN2014MN01521A (es)
UA110338C2 (en) Chemical compounds
UA108510C2 (en) Cyclopropane compound
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
PH12014502413A1 (en) Cyclic bridgehead ether dgat1 inhibitors
MX2014011752A (es) Compuestos heterobiciclicos n-sustituidos y derivados para combatir plagas de animales ii.
MA35086B1 (fr) Compose de triazolopyridine
PE20141940A1 (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
IN2014CN04449A (es)
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
AR084019A1 (es) DERIVADOS DE BENZAMIDA COMO BLOQUEADORES DE IKACh
CR20130476A (es) Derivados de pirazolidin-3-ona
CO6640201A2 (es) Moduladores de crth2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal